Isolated hepatic perfusion for liver metastases of malignant melanoma

Melanoma Research

Volumn 18, Issue 2, 2008, Pages 120-126

  Rizell, Magnus ^a   Mattson, Jan ^a   Cahlin, Christian ^a   Hafström, Larsolof ^a   Lindner, Per ^a   Olausson, Michael ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Hyperthermic liver perfusion; Malignant melanoma; Melphalan; Ocular melanoma

Indexed keywords

CISPLATIN; MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; HUMAN; LIVER FAILURE; LIVER METASTASIS; LIVER PERFUSION; MELANOMA; MORBIDITY; MULTIPLE ORGAN FAILURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; HUMANS; LIVER NEOPLASMS; MELANOMA; MELPHALAN; MIDDLE AGED; SKIN NEOPLASMS;

EID: 40849095988     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3282f8e3c9     Document Type: Article

References (26)

1. Pyrhönen S. The treatment of metastatic uveal melanoma. Eur J Cancer 1998; 34 (Suppl 3):S27-S30.
2. Bedikian AY, Legha SS, Mavligit G, Carrasco CH, Khorana S, Plager C, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 1995; 76:1665-1670.
3. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17600 melanoma patients: validation of the American Joint Committee on cancer melanoma staging system. J Clin Oncol 2001; 19:3622-3634.
4. Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer 2007; 109:455-464.
5. Sasse AD, Sasse EC, Clark LG, Ulloa L, Clark OA, Clark OAC, et al. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev 2007:CD005413.
6. Hafström L, Rudenstam CM, Holmberg SB, Scherstén T, Ehrssson H. The pharmacokinetics of melphalan in regional hyperthermic liver perfusion. Reg Cancer Treat 1990; 3:23-25.
7. Parsons PG, Carter FB, Morrison L, Regius Mary Sister. Mechanism of melphalan resistance developed in vitro in human melanoma cells. Cancer Res 1981; 41:1525-1534.
8. Stehlin JS, Giovanella BC, de Ipolyi PD, Muenz LR, Anderson RF. Results of hyperthermic perfusion for melanoma of the extremities. Surg Gynecol Obstet 1975; 140:339-348.
9. Lienard D, Lejeune FJ, Ewalenko P. In transit metastases of malignant melanoma treated by high dose rTNA-alpha in combination with interferon-gamma and melphalan in isolation perfusion. World J Surg 1992; 16:234-240.
10. Lindner P, Doubrovsky A, Kam PC, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002; 9:127-136.
11. Alexander HR Jr, Libutti SK, Pingpank JF, Bartlett DL, Helsabeck C, Beresneva T. Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. Ann Surg Oncol 2005; 12:138-144. Epub 2005 Feb 4.
12. Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery 2001; 129:176-187.
13. Rothbarth J, Tollenaar RA, Schellens JH, Nortier JW, Kool LJ, Kuppen PJ, et al. Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives. Eur J Cancer 2004; 40:1812-1824.
14. Oldhafer KJ, Lang H, Frerker M, Moreno L, Chavan A, Flemming P, et al. First experience and technical aspects of isolated liver perfusion for extensive liver metastasis. Surgery 1998; 123:622-631.
15. Hafström L, Naredi P. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia TNF alpha and melphalan: Swedish experience. Recent Results Cancer Res 1998; 147:120-126.
16. Alexander HR Jr, Libutti SK, Pingpank JF, Steinberg SM, Bartlett DL, Helsabeck C, et al. Hyperthermic isolated hepatic perfusion (IHP) using melphalan using melphalan for patients with ocular melanoma metastatic to the liver. Clin Cancer Res 2003; 9:6343-6349.
17. Noter SL, Rothbarth J, Pijl ME, Keunen JE, Hartgrink HH, Tijl FG, et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of uvael melanoma confined to the liver. Melanoma Res 2004;14:67-72.
18. Hafström L, Holmberg SB, Naredi P, Lindnér PG, Bengtsson A, Tidebrant G, Scherstén T. Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surg Oncol 1994; 3:103-108.
19. Lindnér P, Fjälling M, Hafström L, Kierulff-Nielsen H, Mattsson J, Schersten T, et al. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan. Eur J Surg Oncol 1999; 25:179-185.
20. Barker WC, Andrich MP, Alexander HR, Fraker DL, Rosenberg SA, Thom AK, et al. Continuous intraoperative external monitoring of perfusate using iodine-131 human serum albumin. Eur J Nucl Med 1995; 22:1242-1248.
21. Eggermont AM, van IJken MG, van Etten B, van der Sijp JR, ten Hagen TL, Wiggers T, et al. Isolated hypoxic hepatic perfusion (IHHP) using balloon catheter techniques: from laboratory to the clinic towards a percutaneous procedure. Hepatogastroenterology 2000; 47:776-781.
22. Van Etten B, Brunstein F, van IJken MG, Marinelli AW, Verhoef C, van der Sijp JR, et al. Isolated hypoxic hepatic perfusion with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques: a phase I and II study. Ann Surg Oncol 2004; 11:598-605.
23. Kresse M, Latta M, Künstle G, Riehle HM, van Rooijen N, Hentze H, et al. Kupffer cell-expressed membrane-bound TNF mediates melphalan hepatotoxicity via activation of both TNF receptors. J Immunol 2005; 175:4076-4083.
24. Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000; 18:3782-3789.
25. Brunstein F, Eggermont AM, de Wiel-Ambagtsheer G, van Tiel ST, Rens J, ten Hagen TLM, et al. Synergistic antitumor effects of histamine plus melphalan in isolated hepatic perfusion for liver metastases. Ann Surg Oncol 2007; 14:795-801. Epub 2006 Nov 10.
26. Van Etten B, Eggermont AM, van Tiel ST, Ambagtsheer G, de Wilt JH, ten Hagen TL. Gene therapy in vivo isolated perfusion models. Curr Gene Ther 2005; 5:195-202.